A carregar...
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) directed against the ABL kinase are now used routinely during frontline therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and result in hematologic remission rates exceeding 90%. Minimal residual disease levels are generally lower wh...
Na minha lista:
| Publicado no: | Leukemia Suppl |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851212/ https://ncbi.nlm.nih.gov/pubmed/27175253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leusup.2012.7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|